High Susanna Gatti's Form 4/A amendment
AmendedDyne Therapeutics, Inc. (DYN) · filed Jul 3, 2024
- Accession no.
- 0000950170-24-081748
- Filed
- Jul 3, 2024
- Trade date
- Jun 21-24, 2024
- Filing delay
- 12 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jun 24, 2024
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.40M. It was filed 12 days after the trade.
This amendment replaces 0000950170-24-077029 (filed Jun 24, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| High Susanna GattiCIK 0001691005 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 21, 2024 | Common Stock | MOption exerciseAcquired | +29,787 | $5.54 | +$165,019.98 | 178,579 | Direct | |
| Jun 21, 2024 | Common Stock | SSaleDisposed | −29,787 | $35.01F2 | −$1,042,842.87 | 148,792 | Direct | |
| Jun 24, 2024 | Common Stock | MOption exerciseAcquired | +10,213 | $5.54 | +$56,580.02 | 159,005 | Direct | |
| Jun 24, 2024 | Common Stock | SSaleDisposed | −10,213 | $35.33F4 | −$360,825.29 | 148,792 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 21, 2024 | Common Stock | MOption exerciseDisposed | −29,787 | $0.00 | $0 | 70,699 | Direct | |
| Jun 24, 2024 | Common Stock | MOption exerciseDisposed | −10,213 | $0.00 | $0 | 60,486 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.63, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
Includes 134,629 unvested RSUs.
- F6
The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter.